TWA
CLDX icon

TCI Wealth Advisors’s Celldex Therapeutics CLDX Stock Holding History

TCI Wealth Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-171
Closed -$6.15K – 591
2023
Q1 		$6.15K Buy
+171
New +$7.38K ﹤0.01% 1389
2022
Q2 		– Sell
-196
Closed -$7K – 2303
2022
Q1 		$7K Sell
196
-30
-13% -$959 ﹤0.01% 1303
2021
Q4 		$9K Buy
226
+69
+44% +$3.01K ﹤0.01% 1237
2021
Q3 		$8K Buy
+157
New +$7.37K ﹤0.01% 1233

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

TCI Wealth Advisors's CLDX Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Celldex Therapeutics (CLDX) in Q2 2023, closing a stake of 171 shares — an estimated $6.15K sold.

TCI Wealth Advisors first reported a position in CLDX in Q3 2021 and held it in 4 quarters. The position peaked at $9K in Q4 2021. 150 funds tracked by Wall St. Rank hold CLDX as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Celldex Therapeutics position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 171 Celldex Therapeutics shares in Q2 2023, an estimated $6.15K.
  • TCI Wealth Advisors first reported a position in Celldex Therapeutics in Q3 2021 and held it in 4 quarters.
  • TCI Wealth Advisors's Celldex Therapeutics position peaked at $9K in Q4 2021.
  • 150 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.